Search Bar & Filters
Found 43 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.
Actively Recruiting
Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and preliminary effects of TQF3250 capsules in adults with type 2 diabetes who are also overweight or obese. This Phase 1b, multi-center, randomized, double-blind, placebo-controlled study plans to enroll 72 participants divided into six dose groups ranging from 4 mg to 40 mg, with a dose-escalation design. Participants will take TQF3250 capsules or a matching placebo orally once daily under fasting conditions for 12 weeks. Each dose group includes 12 subjects, randomized in a 102 ratio to receive either the study drug or placebo. The dosing will follow a titration regimen, gradually increasing to the target dose. During the study, participants will have regular assessments including safety evaluations such as monitoring adverse events and clinical examinations. Pharmacokinetic measurements will be taken at multiple time points before and after dosing, while efficacy will be evaluated through tests like glycated hemoglobin HbA1c, oral glucose tolerance test, body weight, waist circumference, body mass index, fasting plasma glucose, C-peptide, and insulin levels. The total participation lasts about 14 weeks, including follow-up for safety and tolerability.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are studying GW01-200 tablets in a phase 1, open-label trial to assess their safety, tolerability, pharmacokinetics, and preliminary effectiveness in adults with advanced tumors, including both solid tumors and blood cancers. The study focuses on participants whose disease has progressed after standard treatments or who have no available standard treatments. Participants receive GW01-200 tablets orally at increasing dose levels to find the recommended dose for further study. The trial includes several parts where participants with advanced solid tumors or relapsedrefractory hematological malignancies are treated with specified doses to monitor effects and responses. During the study, participants will undergo assessments of adverse events, drug concentration in the body, and tumor response over up to approximately 2 years. Researchers will monitor safety, preliminary treatment effects, and pharmacokinetic properties through regular evaluations and follow-ups throughout the trial duration.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the pan-KRAS inhibitor JAB-23E73 in adults with advanced solid tumors that have KRAS gene alterations, including mutations or amplifications. This open-label, multicenter study is conducted in two phases Phase 1 dose escalation and Phase IIa dose expansion. It aims to find the best dose and assess the drugs effects in patients with KRAS-altered non-small cell lung cancer and other tumors. The study involves taking JAB-23E73 orally as a single agent. In Phase 1, researchers will escalate doses to determine the maximum tolerated dose or recommended phase 2 dose. Following this, Phase 1b will optimize dosing, and Phase 2a will expand to test efficacy, safety, and drug behavior in selected patients. Two alternative doses will be selected for further evaluation based on earlier phase results. Participants will undergo regular assessments including tumor measurements using RECIST v1.1, organ function tests, and monitoring of adverse events and drug levels in the body. The primary outcomes include dose-limiting toxicities during Phase 1 and objective response rate during Phase 2a, with follow-up lasting up to approximately two years. Safety, progression, survival, and pharmacokinetic data will also be collected throughout the study period.
Actively Recruiting
Researchers are evaluating a phase IbII study of ATG-022 plus pembrolizumab with or without chemotherapy in participants who have Claudin 18.2-positive, HER2-negative, PD-L1 positive advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The study targets adults who have either progressed after prior systemic therapy or who have not received any systemic therapy for their condition. The study aims to assess the combination treatments for this specific cancer type. Participants receive either ATG-022 plus pembrolizumab alone or combined with chemotherapy CAPOX regimen, including capecitabine and oxaliplatin. The ATG-022 and pembrolizumab drugs are given every 21 days as one cycle, while the CAPOX chemotherapy is administered in 3-week cycles for up to 8 cycles. The study begins with the evaluation of ATG-022 plus pembrolizumab alone, and the addition of chemotherapy will start based on clinical data from this initial group. Throughout the study, participants undergo tumor testing, imaging, and clinical evaluations to measure safety and effectiveness. Researchers monitor adverse events, dose-limiting toxicities, and treatment responses for up to 12 months after enrollment. Blood samples are collected to analyze drug concentrations. Participants are closely followed to assess overall response, duration of response, and progression-free survival, ensuring comprehensive safety and treatment effect data collection.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus T2DM who are already being treated with insulin and other glucose-lowering medications. This Phase III study focuses on adults with T2DM who have had the condition for at least 90 days and meet certain health criteria. Participants will be randomly assigned to one of three groups elecoglipron at dose level 1, elecoglipron at dose level 2, or placebo. All treatments are taken orally once daily. The study treatment period lasts up to 40 weeks, during which participants continue their background insulin and glucose-lowering medications. During the study, participants will have regular assessments to monitor changes in blood sugar control, including Hemoglobin A1c HbA1c, body weight, blood pressure, and insulin dose. Researchers will also track safety, side effects, and tolerability. The main outcome is the change in HbA1c from baseline to Week 40. Overall, participation involves visits for monitoring and evaluations over approximately 40 weeks.
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
1-10 of 43
1